1	Investigation of ceftriaxone-resistant Neisseria gonorrhoeae detected in Scotland, 2018-2024
2	
3	Martin P McHugh ^{1,2,3} *, Kirsty Aburajab ⁴ , Alexandra Maxwell ⁵ , John Anderson ¹ , Fraser Cairns ¹ ,
4	Seb Cotton ^{1,2} , Andrew Gough ¹ , Brian Malloy ¹ , Katharine Mathers ¹ , Lynne Renwick ¹ , Jill
5	Shepherd ¹ , Kate E Templeton ^{1,2}
6	
7	¹ NHS Lothian, Edinburgh, United Kingdom
8	² Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom
9	³ School of Medicine, University of St Andrews, St Andrews, United Kingdom
10	⁴ NHS Forth Valley, Falkirk, United Kingdom
11	⁵ NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
12	
13	*Corresponding author: Martin P McHugh, v1mmchug@ed.ac.uk
14	ORCID: 0000-0002-0370-3700
15	
16	ABSTRACT
17	
18	Objectives: Describe the clinical, phenotypic, and genomic characteristics of ceftriaxone-
19	resistance Neisseria gonorrhoeae from Scotland
20	Methods: Cases were identified in routine care from 2018-2024. Minimum inhibitory
21	concentrations were determined for seven antimicrobial agents. Whole genome sequencing
22	was performed with Illumina and Oxford Nanopore Technology instruments. A phylogeny
23	containing global ceftriaxone-resistant genomes was generated with Parsnp. A collection of
24	ST8780 genomes was also analysed to give further context using reference based mapping with
25	Snippy.
26	Results: There were five cases of ceftriaxone-resistant N. gonorrhoeae detected. One case
27	(MLST ST1903) clustered within the FC428 lineage in a returning traveller from an Asia-Pacific
28	country. Two cases belonged to the recently described extensively drug resistant MLST
29	ST16406, a returning traveller from an Asia-Pacific country and a sexual contact within

30	Scotland. The final two cases were a resident of an Asia-Pacific country and a sexual contact
31	within Scotland, both belonged to MLST ST8780. These were distinct from other publicly
32	available ST8780 genomes suggesting a novel introduction of the mosaic <i>penA</i> 60.001 allele. All
33	cases were initially treated with ceftriaxone-based regimes, four returned for test of cure and
34	showed clearance of infection.
35	Conclusions: As ceftriaxone resistance is increasingly identified, multiple public health
36	interventions are required to reduce the impact of resistance on gonorrhoea treatment
37	globally.
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	

- 59 INTRODUCTION
- 60

Neisseria gonorrhoeae is a leading cause of sexually transmitted infections globally. WHO
includes *N. gonorrhoeae* on the list of Priority Pathogens due to significant antimicrobial
resistance (AMR), reflecting the significant global health challenge posed by this pathogen [1].
Currently, ceftriaxone is the backbone of gonorrhoeae treatment. Ceftriaxone resistance has
been increasingly identified particularly associated with countries in the Asia-Pacific region, and
in recent years extensively drug-resistant (XDR) cases with few treatment options have been
described [2–5].

We describe the identification, clinical management, laboratory, and genomic investigation of
five ceftriaxone-resistant *N. gonorrhoeae* isolated in Scotland.

71

72 MATERIALS AND METHODS

73

74 This study describes five cases of ceftriaxone-resistant *N. gonorrhoeae* identified in Scotland as 75 part of routine surveillance undertaken by the Scottish Bacterial Sexually Transmitted Infections 76 Reference Laboratory between 2018-2024. All N. gonorrhoeae isolates were submitted by 77 regional diagnostic laboratories for antimicrobial sensitivity testing (AST) and further 78 characterisation. Species identification was confirmed with biochemical testing and MALDI-TOF 79 (Bruker). AST was performed by agar incorporation and Etest strips (BioMerieux), minimum 80 inhibitory concentrations (MICs) were interpreted with EUCAST v14.0 breakpoints. Genomic 81 DNA was extracted from culture suspensions, short read libraries were prepared with the 82 Illumina DNA Prep kit and sequenced on a MiSeg or NextSeg 2000 (Illumina). Short reads were 83 trimmed with Trimmomatic v0.39 and assembled with SPAdes v3.15.5 (with the --isolate and --84 cov-cutoff 15 options). PyngoST was used to perform multilocus sequencing typing (MLST) and 85 *N. gonorrhoeae* sequence typing for antimicrobial resistance (NG-STAR). Resistance markers 86 were identified from assemblies using PathogenWatch. Published sequences from ceftriaxone-87 resistant N. gonorrhoeae were used for global context (Table S1), a core genome alignment was

88 generated and recombination masked with Parsnp v1.5.3, and the phylogeny visualised with 89 iTOL v6. To further investigate ST8780, short reads were downloaded from the NCBI Short Read 90 Archive (Table S2), trimmed, mapped to the WHO O reference genome (Accession 91 NZ CP145037.1) with Snippy v4.6.0, recombination masked with Gubbins v2.4.1, and the 92 resulting phylogeny visualised with iTOL. Long reads were generated for SGC-24-001 and SGC-93 24-002 using the Rapid Barcoding v14 library preparation kit and an R10.4.1 flowcell on a 94 GridION sequencer with super high accuracy basecalling in MinKNOW v24.02.16. Long reads 95 were quality filtered with Filtlong v0.2.1 and assemblies generated with Flye v2.9.3 (with the --96 nano-hq and --genome-size 2.3m options). Resulting assemblies were polished with Medaka 97 v1.11.3, Polypolish v0.6.0, and Pypolca 0.3.1. Patient demographics and treatment histories 98 were retrieved from electronic health records.

- 99
- 100
- 101 **RESULTS**
- 102 Case 1, SGC-23-001
- 103

104 Case 1 (SGC-23-001) was a male who presented to sexual health services in 2018 with urethral 105 discharge after unprotected sex in an Asia-Pacific country (Table S3). Urine was NAAT positive 106 for N. gonorrhoeae and a urethral swab grew N. gonorrhoeae. The patient was given a 500mg 107 intramuscular dose of ceftriaxone and 1g oral azithromycin as per national treatment guidance 108 at the time. Fourteen days after empirical treatment AST results were reported which showed 109 multidrug resistance including ceftriaxone (MIC 0.75 mg/L) and cefixime (MIC 2.0 mg/L), but not 110 azithromycin (MIC 0.25 mg/L) and the patient was given a further 2g oral dose of azithromycin 111 (Table S4). Test of cure (TOC) NAAT was negative. No sexual contacts within Scotland were 112 identified.

113

114 Case 2, SGC-23-002

115

116	The second case (SGC-23-002) was a male who presented to sexual health services in 2022 with
117	a two week history of urethral discharge and dysuria after unprotected sex in an Asia-Pacific
118	country (Table S3). The urine NAAT was positive, and <i>N. gonorrhoeae</i> was grown from a
119	urethral swab. Intramuscular ceftriaxone (1g) was given, and the patient had a negative TOC
120	two weeks later. AST identified this as an XDR strain with non-susceptibility to six of the seven
121	tested agents, including ceftriaxone (MIC 0.19 mg/L), cefixime (2.0 mg/L), and high level
122	resistance to azithromycin (MIC >256.0 mg/L; Table S4).
123	
124	Case 3, SGC-23-003
125	
126	Case 3 (SGC-23-003) was a female sexual contact of case 2 in Scotland, case 2 and 3 reported no
127	other recent sexual contacts (Table S3). The patient reported two days of abdominal pain, on
128	examination profuse discharge was found but no evidence of pelvic inflammatory disease. A
129	vaginal swab was NAAT positive and <i>N. gonorrhoeae</i> was isolated from a cervical swab.
130	Intramuscular ceftriaxone (1g) was given, and the patient had a negative TOC two weeks later.
131	AST results were similar to case 2 although the ceftriaxone MIC was slightly higher (MIC 0.38
132	mg/L; Table S4).
133	
134	Case 4, SGC-24-002
135	
136	Case 4 (SGC-24-002) was an asymptomatic female who tested NAAT positive on a vaginal swab
137	after unprotected sex in 2024 (Table S3). The patient was treated with intramuscular
138	ceftriaxone (1g) and was negative at TOC. AST showed multidrug resistance including
139	ceftriaxone (MIC 0.75 mg/L) and cefixime (MIC 2.0 mg/L; Table S4). Only one sexual partner was
140	identified.
141	
142	Case 5, SGC-24-001
143	

144 Case 5 (SGC-24-001) was the male sexual contact of case 4 in Scotland. Case 5 reported two 145 other female sexual contacts, but these individuals could not be traced for testing (Table S3). 146 Case 5 reported dysuria and urethral discharge for one week prior to presentation. The urine 147 NAAT was positive, and *N. gonorrhoeae* was grown from a urethral swab. AST showed the same 148 multidrug resistance as case 4 with slightly higher cephalosporin MICs (ceftriaxone MIC 1.0 149 mg/L and cefixime MIC 3.0 mg/L; Table S4). Intramuscular ceftriaxone (1g) was given at 150 presentation, when culture results were reported the patient was further treated with 151 intramuscular gentamicin (240mg) and oral azithromycin (2g). The patient was a resident of an 152 Asia-Pacific country and moved back before TOC was performed, further follow-up has been 153 unsuccessful.

154


155 Genomic investigation

156

157 Genotypic mechanisms conferring all detected phenotypic resistance were identified in the 158 genomes, including the mosaic penA-60.001 conferring cephalosporin resistance, gyrA and parC 159 mutations conferring ciprofloxacin resistance, and the *rpsJ* V57M polymorphism and *tetM* 160 conferring tetracycline resistance (Table S5). The isolates belonged to diverse sequence types 161 which suggested distinct origins. Phylogenetic analysis with a background of international 162 ceftriaxone-resistant isolates revealed that SGC-23-001 clustered within a diverse clade 163 containing MLST ST1903 and related STs identified in 2015-2021 from China and five other 164 countries (Figure 1). SGC-23-001 was also assigned to NG-STAR ST233 which was common in 165 this clade, indicating the presence of similar AMR mechanisms. The closest match in this 166 dataset was the FC428 type strain from Japan in 2015 (428 single nucleotide polymorphisms 167 [SNPs]). SGC-23-002 and SGC-23-003 differed from each other by two SNPs, consistent with 168 direct transmission as supported by partner notification. Additionally, the two genomes 169 differed by a median of 4 SNPs (range 1-7 SNPs) to three other MLST ST16406 and NG-STAR 170 ST4465 genomes identified in Austria, England, and France in 2022 (Figure 1). High-level 171 azithromycin resistance was conferred by the 23S rDNA A2059G mutation (Escherichia coli 172 numbering). No SNPs were identified between SGC-24-001 and SGC-24-002 which supports

173 direct transmission. Additionally, these two genomes were distinct in this analysis differing to 174 the nearest genome (GD2021236 from China in 2021) by 3430 SNPs. SGC-24-001 and SGC-24-175 002 were assigned to MLST ST8780 and NG-STAR ST5998, this was a novel NG-STAR ST 176 indicating these genomes are unique within the global database. To further investigate the 177 origins of SGC-24-001 and SGC-24-002, a collection of MLST ST8780 genomes were identified 178 and a phylogeny generated (Figure S1). The Scottish isolates were the only ones containing the 179 mosaic penA-60.001 allele, indicating that this is a novel acquisition of ceftriaxone resistance in 180 this ST. The Scottish isolates were most closely related to an isolate from Thailand in 2018 (949 181 SNPs). SGC-24-001 and SGC-24-002 carried the cryptic plasmid, conjugative plasmid, and the 182 African-type β -lactamase (*bla*_{TEM-1}) plasmid.

183



- 185 Figure 1 Maximum-likelihood phylogeny of five Scottish and 62 international ceftriaxone-
- 186 resistant *N. gonorrhoeae*. Scottish genomes are highlighted in purple. Metadata bars coloured
- 187 as per figure legend.

- **DISCUSSION**

192 We describe five cases of ceftriaxone-resistant N. gonorrhoeae acquired in, or involving 193 residents of, Asia-Pacific countries identified in Scotland. Case 1 from 2018 belonged to the 194 FC428-related clone (MLST ST1903) which has acquired the mosaic *penA* allele and is frequently 195 identified in the Asia-Pacific [4]. Cases 2 and 3 from 2022 belonged to ST16406 and were 196 resistant to current first-line antimicrobial agents ceftriaxone, azithromycin, and ciprofloxacin. 197 ST16406 was first described in 2022 and has been identified in travellers returning from the 198 Asia-Pacific region to Austria, England, and France [2,3,5]. We identified a median of 4 SNPs 199 between cases identified in Austria, England, France, and Scotland which reflects the short 200 collection time (all in 2022) but also suggests a rapidly spreading clone. To our knowledge, 201 cases 4 and 5 are the first ST8780 identified with ceftriaxone resistance. ST8780 belongs to the 202 generally antimicrobial-susceptible genomic lineage B of *N. gonorrhoeae*, indicating that mosaic 203 penA 60.001 is spreading further within the global population as recently identified by 204 Golparian et al [6]. Concerningly, Case 5 reported two sexual contacts who could not be traced 205 and may lead to further ceftriaxone-resistant cases within Scotland. 206 Four patients were successfully treated with ceftriaxone-based regimes despite in vitro 207 resistance, the remaining patient did not return for TOC. There is growing evidence that the 208 ceftriaxone resistance breakpoint is too low for genital infections, although treatment success 209 at other sites such as the oropharynx need to be considered in any breakpoint change [7-9]. 210 We also identified different cephalosporin MICs within two transmission pairs, although the 211 reported values are within the expected variability of the method (\pm two doubling dilutions). 212 Our reliance on cultured isolates is a potential limitation as ~50% of gonorrhoea cases in 213 Scotland are diagnosed by NAAT only and no isolate is available. It is possible that culture-214 negative ceftriaxone resistant cases have occurred that would not be included in our study. To 215 reduce the impact of this, patients that remain symptomatic after treatment are reviewed to 216 ascertain if ceftriaxone resistance may be present. 217

- 218
- 219 CONCLUSION
- 220

221	Resistance to ceftriaxone poses a significant risk to N. gonorrhoeae treatment guidelines
222	globally, although in the cases described here who had TOC first line agents were successful.
223	Efforts to expand access to rapid molecular diagnostics to determine sensitivity to ceftriaxone
224	and alternative agents are required to reduce the selection of resistance, and the introduction
225	of novel therapeutic agents must be carefully managed and combined with robust surveillance
226	to identify emerging resistance. The 4CMenB vaccine has been approved in the UK for
227	individuals at high risk of gonorrhoea, the effect of this vaccine on infections and AMR should
228	be closely monitored. Finally, sustained messaging to reduce STI transmission both domestically
229	and in international travellers should be prioritised.
230	
231	
232	ETHICS STATEMENT
233	
234	Ethical approval for this work was granted by the Lothian National Research Scotland
235	BioResource (Reference 20/ES/0061)
236	
237	
238	COMPETING INTERESTS
239	
240	None declared
241	
242	
243	FUNDING STATEMENT
244	
245	This work was funded by NHS National Services Scotland via the Scottish Bacterial Sexually
246	Transmitted Infections Reference Laboratory
247	
248	
249	DATA AVAILABILITY STATEMENT

2	5 0
	NU
~	20

251 Sequence data has been uploaded to the European Nucleotide Archive (BioProject PRJEB73456) 252

253

254 **ACKNOWLEDGEMENTS**

- 255
- 256 We would like to thank Matthew Holden, Sharif Shaaban, and Lesley Wallace for providing
- 257 feedback on the manuscript. We thank diagnostic microbiology laboratories for providing
- 258 isolates for characterisation.
- 259
- 260

261 CONTRIBUTIONS

- 262
- 263 MPM: conceptualisation, methodology, data curation, investigation, writing original draft,
- 264 guarantor; KA, AM, JA, FC, SC, AG, BM, KM, LR and JS: data curation, writing review and
- 265 editing; KET: conceptualisation, writing review and editing
- 266
- 267

268 **REFERENCES**

- 269
- WHO. WHO Bacterial Priority Pathogens List, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva, Switzerland: World Health Organisation 2024.
- 273 2 Maubaret C, Caméléna F, Mrimèche M, et al. Two cases of extensively drug-resistant (XDR)
- 274 Neisseria gonorrhoeae infection combining ceftriaxone-resistance and high-level
- azithromycin resistance, France, November 2022 and May 2023. *Eurosurveillance*.
- 276 2023;28:2300456. doi: 10.2807/1560-7917.ES.2023.28.37.2300456
- 277 3 Day M, Pitt R, Mody N, *et al.* Detection of 10 cases of ceftriaxone-resistant Neisseria
 278 gonorrhoeae in the United Kingdom, December 2021 to June 2022. *Eurosurveillance*.
 279 2022;27:2200803. doi: 10.2807/1560-7917.ES.2022.27.46.2200803

- 280 4 Tang Y, Liu X, Chen W, et al. Antimicrobial Resistance Profiling and Genome Analysis of the
- 281 penA-60.001 Neisseria gonorrhoeae Clinical Isolates in China in 2021. *J Infect Dis*.
- 282 2023;228:792–9. doi: 10.1093/infdis/jiad258
- Pleininger S, Indra A, Golparian D, *et al.* Extensively drug-resistant (XDR) Neisseria
 gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus
 azithromycin in Austria, April 2022. *Eurosurveillance*. 2022;27:2200455. doi: 10.2807/15607917.ES.2022.27.24.2200455
- 6 Golparian D, Vestberg N, Södersten W, *et al.* Multidrug-resistant Neisseria gonorrhoeae
 isolate SE690: mosaic penA-60.001 gene causing ceftriaxone resistance internationally has
 spread to the more antimicrobial-susceptible genomic lineage, Sweden, September 2022. *Eurosurveillance.* 2023;28:2300125. doi: 10.2807/1560-7917.ES.2023.28.10.2300125
- 291 7 Eyre DW, Sanderson ND, Lord E, *et al.* Gonorrhoea treatment failure caused by a Neisseria
- 292 gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance,
- 293 England, February 2018. *Eurosurveillance*. 2018;23:1800323. doi: 10.2807/1560-
- 294 **7917.ES.2018.23.27.1800323**
- 8 Unemo M, Golparian D, Oxelbark J, *et al.* Pharmacodynamic evaluation of ceftriaxone single dose therapy (0.125-1 g) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant
 Neisseria gonorrhoeae strains in a hollow fibre infection model for gonorrhoea. *J Antimicrob Chemother.* 2024;79:1006–13. doi: 10.1093/jac/dkae063
- 299 9 Caméléna F, Mérimèche M, Brousseau J, *et al.* Emergence of Extensively Drug-Resistant
 300 Neisseria gonorrhoeae, France, 2023 Volume 30, Number 9—September 2024 Emerging
 301 Infectious Diseases journal CDC. doi: 10.3201/eid3009.240557
- 302
- 303
- 304
- 305